This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Surprise Coming for Amedisys (AMED) This Earnings Season?
by Zacks Equity Research
Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Higher Business Volumes Aid Teladoc (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 earnings are likely to reflect higher visit volumes and subscriptions, along with an increase in marketing expenses.
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Amedisys (AMED) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amedisys (AMED) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Varian (VAR) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
Varian's (VAR) receipt of 13 Ethos orders in fiscal Q1 raises investors' optimism on the stock.
Encompass Health (EHC) Steadily Grows Inpatient Rehab Business
by Zacks Equity Research
Encompass Health (EHC) is continuously investing in post acute care services, which are in huge demand in the United States.
3 Biggest MedTech Trends to Watch in 2021 for Better Returns
by Sriparna Ghosal
Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.
Abbott (ABT) to Expand in Booming TBI Space on New Approval
by Zacks Equity Research
If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.
Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails
by Zacks Equity Research
Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.
Hologic (HOLX) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.
Hologic (HOLX) Rides on Robust Preliminary Q1 Organic Sales
by Zacks Equity Research
The uptick in Hologic's (HOLX) Diagnostics sales is likely the result of increased demand for COVID-19 testing.
AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.
Hologic (HOLX) to Expand in Oncology With Biotheranostics Buyout
by Zacks Equity Research
Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.
Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal first-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.
Henry Schein (HSIC) Grows Inorganically, Closes JV, Buys Stake
by Zacks Equity Research
The developments are expected to strengthen Henry Schein's (HSIC) presence in high potential and still-untapped markets.
Hologic (HOLX) Completes SOMATEX Buyout, Expands Portfolio
by Zacks Equity Research
Hologic (HOLX) to expand biopsy portfolio as well as enhance patient experience via the SOMATEX buyout.
What Makes Amedisys (AMED) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Encompass Health (EHC) Gain From Inpatient Rehab Business?
by Zacks Equity Research
Encompass Health (EHC) is resorting to business restructuring to focus on core growth areas, which should expand its returns.
Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Amedisys (AMED) Down 5.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Banks on Home Health & Hospice Amid Cost Woe
by Zacks Equity Research
Amedisys (AMED) continues to benefit from the recent acquisitions of hospice care providers.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
3 Reasons Why Amedisys (AMED) Is a Great Growth Stock
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.